Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
Curcuma longa may leads to higher global symptoms of dyspepsia (responders) compared with placebo (low certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
Curcuma longa showed no clear difference in adverse events Assessed clinically compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
STW5 (Iberogast) showed no clear difference in global symptoms of dyspepsia (responders) compared with placebo (low certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
STW5 (Iberogast) showed no clear difference in adverse events Assessed clinically compared with placebo (low certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
Peppermint/caraway oil probably leads to higher global symptoms of dyspepsia (responders) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
Peppermint/caraway oil showed no clear difference in adverse events Assessed clinically compared with placebo (low certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia · patients with functional dyspepsia
1 finding from 1 review
Harmful alcohol use · alcohol use disorder
1 finding from 1 review
Retention [ · alcohol use disorder
Pharmacologic intervention showed no clear difference in retention compared with placebo (low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid may leads to lower risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of myocardial infarction (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review